What happened
Shares of developmental-stage biopharma Checkpoint Therapeutics (NASDAQ: CKPT) rose by as much as 16% in pre-market action Tuesday morning. The biotech stock was heating up in response to a positive late-stage trial readout for cosibelimab, its experimental metastatic cutaneous squamous cell carcinoma therapy, along with two follow-on price target upgrades from H.C. Wainwright analyst Joseph Pantginis and Cantor Fitzgerald analyst Jennifer Kim.
So what
In its pre-market press release, Checkpoint said that cosibelimab produced an impressive 47.4% confirmed objective response rate in its registration-enabling trial for metastatic cutaneous squamous cell carcinoma. What's key to understand is that the company's advanced skin cancer drug could be a best-in-class product if these data stand up to the scrutiny of a formal regulatory review.
Image source: Getty Images.
And in light of this promising late-stage trial data, the analysts at H.C. Wainwright and Cantor Fitzgerald are both suggesting that the developmental-stage biotech stock could appreciate by more than 800% over the next 12 months. With that kind of glowing optimism from Wall Street, it's no surprise that Checkpoint's shares are perking up in a big way Tuesday morning.
Now what
Are these sky-high price targets realistic? Cosibelimab's peak annual sales have been estimated to be as high as $1.3 billion. Checkpoint's market cap, as of Monday's closing bell, was under $250 million. So there is a solid rationale for these jaw-dropping price targets. That being said, Checkpoint still has a long road to travel before it can start booking sales. As such, this promising clinical-stage cancer stock is still best suited for the risk-tolerant crowd.
10 stocks we like better than Checkpoint Therapeutics, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Checkpoint Therapeutics, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of January 10, 2022
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
